Who is sponsoring NCT05739942?

NCT05739942 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT05739942?

Interventions in NCT05739942: [177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide.

What condition does NCT05739942 study?

NCT05739942 studies Newly Diagnosed and Recurrent Glioblastoma.

Is NCT05739942 still recruiting?

NCT05739942 is currently active, enrolled. Last updated 3 February 2026.

Last reviewed 2026-02-03 · How we verify

NCT05739942

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Active, enrolled Phase 1 Last updated 3 February 2026

What this trial tests

Phase 1 trial testing [177Lu]Lu-NeoB in Newly Diagnosed and Recurrent Glioblastoma in 42 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 May 2024

Primary endpoint
10 December 2026

8 November 2028

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	15 May 2024
Primary completion	10 December 2026
Estimated completion	8 November 2028
Sites	23 locations across Portugal, United States, Germany, Spain, Italy, France

Drugs / interventions tested

[177Lu]Lu-NeoB — full drug profile →
[68Ga]Ga-NeoB — full drug profile →
Temozolomide (temozolomide) — full drug profile →

Conditions studied

Newly Diagnosed and Recurrent Glioblastoma — all drugs for Newly Diagnosed and Recurrent Glioblastoma →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 100, any sex, with Newly Diagnosed and Recurrent Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will investigate different doses of \[177Lu\]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of \[177Lu\]Lu-NeoB in combination with the SoC and in recurrent glioblastoma as single agent, to identify the recommended dose and to also explore the safety of the PET imaging agent \[68Ga\]Ga-NeoB and characterize its uptake in the tumor area.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.
Song J, Yang P, Chen C, Ding W, et al · · 2025 · cited 40× · PMID 40675967 · DOI 10.1038/s41392-025-02266-z
PET imaging of gliomas: Status quo and quo vadis?
Galldiks N, Lohmann P, Friedrich M, Werner JM, et al · · 2024 · cited 21× · PMID 38970818 · DOI 10.1093/neuonc/noae078
Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting.
Damiana TST, Paraïso P, de Ridder C, Stuurman D, et al · · 2023 · cited 12× · PMID 37584725 · DOI 10.1007/s00259-023-06364-4
Radioligand Therapy in Cancer Management: A Global Perspective.
Ninatti G, Lee ST, Scott AM. · · 2025 · cited 5× · PMID 41228206 · DOI 10.3390/cancers17213412
Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials.
Palihati M, Das JP, Yeh R, Capaccione K. · · 2025 · cited 5× · PMID 40863874 · DOI 10.3390/tomography11080083
Innovative radiotherapies for the treatment of glioblastoma.
Van Eupen L, Waked A, Primac I, Vermeulen K, et al · · 2026 · PMID 41684714 · DOI 10.1093/noajnl/vdaf255

Verify or expand the search:

Other trials of [177Lu]Lu-NeoB

Trials testing the same drug.

NCT06247995 — A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GR · Phase 1, PHASE2 · recruiting
NCT06379217 — NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastati · Phase 1 · active not recruiting
NCT05870579 — [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast · Phase 1 · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05739942 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 3 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05739942.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing